Skip to main content
Premium Trial:

Request an Annual Quote

Owkin, Stanford Medicine Collaborate on AI-Driven Lung Cancer, Mesothelioma Biomarker Discovery

NEW YORK – Owkin said Tuesday that it has formed a collaboration with Stanford Medicine to apply artificial intelligence to molecular and other data to inform drug discovery and ultimately improve the treatment of lung cancer and mesothelioma. The partners will also conduct a clinical study but did not provide details.

The French bioinformatics company and the academic health system will use multimodal data from Stanford to support biomarker discovery as a first step in therapeutic development. They then will look for potential treatment targets by seeking to advance understanding of treatment resistance mechanisms.

Owkin is sponsoring the study but did not say how much money it is contributing.

"By combining our expertise in AI with Stanford Medicine's high-quality multimodal patient data, we hope to better understand the treatment of lung cancer and mesothelioma and make a lasting difference to the lives of patients worldwide," Dinesh Divakaran, Owkin's VP of partnerships for North America, said in a statement.

Owkin CSO and Cofounder Gilles Wainrib is a former postdoctoral fellow at Stanford.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.